ESG Performance Data
The following ESG Performance Data is also available as an Excel download.
Financial Results
Financial Results (Millions) | 2021 | 2020 | 2019 |
---|---|---|---|
Total sales | $93,775 | $82,584 | $82,059 |
Net earnings | $20,878 | $14,714 | $15,119 |
Market price per share (year-end close) | $171.07 | $157.38 | $145.87 |
R&D investment | $14,714 | $12,159 | $11,355 |
Sales by business segment | placeholder |
placeholder |
placeholder |
Pharmaceutical | $52,080 | $45,572 | $42,198 |
MedTech | $27,060 | $22,959 | $25,963 |
Consumer Health | $14,635 | $14,053 | $13,898 |
Number of consecutive years of dividend increases1 | 60 | 59 | 58 |
Tax Contribution (Billions)
Tax Contribution (Billions) | 2021 | 2020 | 2019 |
---|---|---|---|
Payroll & social insurance taxes borne | $1.5 | $1.3 | placeholder |
Payroll & social insurance taxes collected | $4.6 | $4.3 | placeholder |
Sales/use & other taxes borne | $0.9 | $0.8 | placeholder |
Sales/use & other taxes collected | $1.3 | $1.0 | placeholder |
Corporate income tax | $4.8 | $4.6 | placeholder |
Total taxes borne | $7.2 | $6.7 | placeholder |
Total taxes collected | $6.0 | $5.3 | placeholder |
Total tax contribution | $13.1 | $12.0 | placeholder |
Global Health Equity
VERMOX Donations | placeholder |
placeholder |
2021 |
---|---|---|---|
Number of VERMOX (mebendazole) doses donated (millions)
|
placeholder |
placeholder |
placeholder |
Annual total1 | placeholder |
placeholder |
220.71 |
Via donations to the WHO | placeholder |
placeholder |
144 |
Via other and private donations | placeholder |
placeholder |
77 |
Cumulative doses donated since the start of the initiative through the WHO and private donations (billions) | placeholder |
placeholder |
2.0 |
Number of countries where VERMOX (mebendazole) doses were donated | placeholder |
placeholder |
55 |
Access to Tuberculosis Treatment
Access to Tuberculosis Treatment | 2021 | 2020 | 2019 |
---|---|---|---|
Annual number of patients receiving access to bedaquiline molecule (branded and generic) | 137,927 | 133,565 | 105,365 |
Access to Medicine
Access to Medicine | 2021 | 2020 | 2019 |
---|---|---|---|
Number of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme | 6 | 6 | 6 |
Number of products on the WHO List of Prequalified Vaccines as part of its Prequalification of Vaccine Programme | 2 | 0 | 0 |
% change in average net price across U.S. product portfolio vs. prior year2 | (2.8)% | (5.7)% | (1.2)% |
Our Giving (Millions)
Our Giving (Millions) | 2021 | 2020 | 2019 |
---|---|---|---|
Total products and cash contributed | $2,738‡ | $2,567+ | $1,806+ |
Products contributed | $2,303‡ | $2,043+ | $1,383+ |
Cash contributed | $435‡ | $524+ | $423+ |
Disaster Relief (Millions)
Disaster Relief (Millions) | 2021 | 2020 | 2019 |
---|---|---|---|
Total allocated for immediate, mid- and long-term response and readiness to natural disasters | $0.29 | $0.57 | $0.70 |
$ worth of Johnson & Johnson products provided to communities impacted by natural disasters | $6.69 | $1.86 | $36.70 |
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 2021 doses donated include VERMOX (mebendazole) chewable and tablet formulations.
2 Represents the year-over-year change in the average net price, which is list price less rebates, discounts and fees.
Our Employees
Global Employees | 2021 | 2020 | 2019 |
---|---|---|---|
Total number of employees1, 2 | 144,315‡ | 136,360+ | 137,701+ |
Women | 49.0%‡ | 48.1%+ | 47.8%+ |
Men | 50.9%‡ | 51.9% | 52.2% |
Declined to answer1 | 0.1%‡ | 0% | Not reported |
Region | placeholder |
placeholder |
placeholder |
Asia Pacific | 29,517‡ | 27,939+ | 28,195+ |
Europe, Middle East & Africa | 42,429‡ | 41,201+ | 42,582+ |
Latin America | 23,441‡ | 20,320+ | 20,182+ |
North America | 48,928‡ | 46,900+ | 46,742+ |
Gender Representation
Gender Representation | 2021 | 2020 | 2019 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||||
Region | placeholder |
placeholder |
placeholder |
||||||||||||
Asia Pacific
|
|
|
|
||||||||||||
Europe, Middle East & Africa |
|
|
|
||||||||||||
Latin America |
|
|
|
||||||||||||
North America |
|
|
|
||||||||||||
Employment type | placeholder |
placeholder |
placeholder |
||||||||||||
Full-time employees |
|
|
|
||||||||||||
Part-time employees |
|
|
|
||||||||||||
Job category3 | placeholder |
placeholder |
placeholder |
||||||||||||
Vice Presidents |
|
|
|
||||||||||||
Managers and Directors4 |
|
|
|
||||||||||||
Professionals4 |
|
|
|
||||||||||||
Management and Executive Positions3 | placeholder |
placeholder |
placeholder |
||||||||||||
Women in management positions |
|
|
|
||||||||||||
Women in executive positions |
|
|
|
Diversity in Board Composition
Diversity in Board Composition | 2021 | 2020 | 2019 |
---|---|---|---|
Women | 35.7%‡ | 35.7%+ | 28.6%+ |
Ethnic/Racial diversity | 21.4%‡ | 21.4%+ | 21.4%+ |
Age Diversity by Job Category
Age Diversity by Job Category | 2021 | 2020 | 2019 |
---|---|---|---|
Vice Presidents | placeholder |
placeholder |
placeholder |
Under 30 | 0%‡ | 0%+ | 0%+ |
30 – 50 | 43.5%‡ | 44.2%+ | 46.3%+ |
51+ | 56.5%‡ | 55.8%+ | 53.7%+ |
Managers and Directors | placeholder |
placeholder |
placeholder |
Under 30 | 1.5%‡ | 1.3%+ | 1.3%+ |
30 – 50 | 72.2%‡ | 72.4%+ | 73.2%+ |
51+ | 26.3%‡ | 26.4%+ | 25.6%+ |
Professionals | placeholder |
placeholder |
placeholder |
Under 30 | 22.7%‡ | 20.7%+ | 21.4%+ |
30 – 50 | 60.0%‡ | 61.7%+ | 61.7%+ |
51+ | 17.3%‡ | 17.5%+ | 16.9%+ |
Ethnic/Racial Diversity in the U.S. by Job Category
Ethnic/Racial Diversity in the U.S. by Job Category | 2021 | 2020 | 2019 |
---|---|---|---|
Vice Presidents | placeholder |
placeholder |
placeholder |
White | 70.7%‡ | 72.7% | 75.4% |
Asian | 11.7%‡ | 11.2% | 10.4% |
Black/African American | 7.3%‡ | 6.6% | 6.7% |
Hispanic/Latino | 8.3%‡ | 8.4% | 6.9% |
Other | 1.9%‡ | 0.9% | 0.6% |
Declined to answer1 | 0.1%‡ | 0.1% | Not reported |
Managers and Directors4 | placeholder |
placeholder |
placeholder |
White | 64.5%‡ | 67.7% | 70.2% |
Asian | 18.3%‡ | 17.2%+ | 16.6%+ |
Black/African American | 6.3%‡ | 5.4%+ | 5.0%+ |
Hispanic/Latino | 7.7%‡ | 7.3%+ | 7.0%+ |
Other | 1.9%‡ | 1.3%+ | 1.2%+ |
Declined to answer1 | 1.4%‡ | 1.1%+ | Not reported |
Professionals | placeholder |
placeholder |
placeholder |
White | 64.2%‡ | 66.4% | 68.0% |
Asian | 13.4%‡ | 12.9%+ | 12.0%+ |
Black/African American | 7.7%‡ | 7.5%+ | 7.6%+ |
Hispanic/Latino | 10.4%‡ | 10.2%+ | 10.4%+ |
Other | 2.5%‡ | 2.2%+ | 2.0%+ |
Declined to answer1 | 1.8%‡ | 0.9%+ | Not reported |
New Employee Hires
New Employee Hires | 2021 | 2020 | 2019 |
---|---|---|---|
Total Number of New Hires | 22,543‡ | 13,594+ | 21,948+ |
Region4 | placeholder |
placeholder |
placeholder |
Asia Pacific | 25.6%‡ | 28.4%+ | 28.9%+ |
Europe, Middle East & Africa | 16.7%‡ | 22.7%+ | 27.0%+ |
Latin America | 29.2%‡ | 22.4%+ | 16.5%+ |
North America | 28.4%‡ | 26.4%+ | 27.6%+ |
Gender representation | placeholder |
placeholder |
placeholder |
Women | 54.0%‡ | 52.5%+ | 51.4%+ |
Men | 45.8%‡ | 47.5%+ | 48.6%+ |
Declined to answer1 | 0.2%‡ | 0%+ | Not reported |
Age | placeholder |
placeholder |
placeholder |
Under 30 | 47.5%‡ | 46.5%+ | 52.7%+ |
30 – 50 | 47.6%‡ | 48.5%+ | 42.8%+ |
51+ | 4.9%‡ | 4.9%+ | 4.5%+ |
Employee Retention and Turnover
Employee Retention and Turnover | 2021 | 2020 | 2019 |
---|---|---|---|
Managers5 and above moved across functions, country or business segment lines | 45.8%‡ | 44.6%+ | 42.6%+ |
Overall voluntary turnover | 8%‡ | 5%+ | 8%+ |
Voluntary turnover of high performers | 4%‡ | 3%+ | 4%+ |
Parental Leave
Parental Leave | 2021 | 2020 | 2019 |
---|---|---|---|
Gender composition of U.S. employees who took parental leave | placeholder |
placeholder |
placeholder |
Women | 43% | 45% | 47% |
Men | 57% | 55% | 53% |
Gender composition of U.S. employees who returned to work after parental leave ended | placeholder |
placeholder |
placeholder |
Women | 93% | 97% | 98% |
Men | 89% | 97% | 100% |
Year-End Performance Reviews Completed by Job Category
Year-End Performance Reviews Completed by Job Category | 2021 | 2020 | 2019 |
---|---|---|---|
Vice Presidents | 87% | 83% | 76% |
Managers and Directors | 94% | 93% | 90% |
Professionals | 95% | 93% | 90% |
Other6 | 87% | 88% | 82% |
Overall for all employees | 94% | 93% | 89% |
Training & Development
Training & Development | 2021 | 2020 | 2019 |
---|---|---|---|
Number of leaders participated in our Enterprise Leader Development Program (annual) | 1,929 | 3,206 | 3,537 |
Number of leaders trained in our Enterprise Leader Development Program (cumulative) | 13,131 | 11,202 | 7,996 |
Number of U.S. and Puerto Rico employees participated in the tuition reimbursement program | 1,189 | 1,178 | 1,262 |
Spend on Employee Learning and Development (Millions)
Spend on Employee Learning and Development (Millions) | 2021 | 2020 | 2019 |
---|---|---|---|
Leadership training and executive coaching | $64 | $18 | $27 |
Professional skills | $63 | $56 | $52 |
Tuition and external certifications | $11 | $16 | $11 |
Operations, administration and e-learning | $10 | $17 | $7 |
Health Care Compliance training | $2 | $2 | $2 |
Total | $150 | $108 | $98 |
2021 Our Voice Survey Results
2021 Our Voice Survey Results |
placeholder |
placeholder |
2021 |
---|---|---|---|
Number of languages available | placeholder |
placeholder |
36‡ |
Number of countries administered | placeholder |
placeholder |
77‡ |
Response rate (among all active employees) | placeholder |
placeholder |
91%‡ |
Increase in participation compared to 2019 (among all eligible employees) | placeholder |
placeholder |
1% |
Favorability rate | placeholder |
placeholder |
82%‡ |
Increase in favorability compared to 2019 on like-to-like questions | placeholder |
placeholder |
2% |
Percentage agreed with the statement: | placeholder |
placeholder |
placeholder |
I am willing to give extra effort to help Johnson & Johnson meet its goals. | placeholder |
placeholder |
94%‡ |
I would recommend Johnson & Johnson as a great place to work. | placeholder |
placeholder |
87%‡ |
In my workgroup, we eliminate practices that stand in the way of achieving results. | placeholder |
placeholder |
71%‡ |
I would like to be working at Johnson & Johnson one year from now. | placeholder |
placeholder |
91%‡ |
Leaders in my organization demonstrate that integrity, quality and compliance are top priorities through their words and actions. | placeholder |
placeholder |
86%‡ |
Employee Resource Groups (ERGs)
Employee Resource Groups (ERGs) | 2021 | 2020 | 2019 |
---|---|---|---|
Number of employees engaged in ERGs | 28,135 | 24,304 | 21,611 |
Number of U.S. ERG chapters | 270 | 260 | 255 |
Number of non-U.S. ERG chapters | 208 | 183 | 176 |
Number of WeSustain teams (global) | 78 | Not reported | Not reported |
Number of countries with WeSustain teams | 32 | Not reported | Not reported |
Number of actions taken in 2021 via the HealthyPlanet platform | 24,609 | Not reported | Not reported |
Employee Safety
Employee Safety | 2021 | 2020 | 2019 |
---|---|---|---|
Employee Safety,7 Global | placeholder |
placeholder |
placeholder |
Lost Workday Case rate8 | 0.06‡ | 0.05+ | 0.07+ |
Total Recordable Injury Rate | 0.30‡ | 0.24+ | 0.31+ |
Serious Injury and Illness Case rate | 0.02‡ | 0.02+ | 0.04+ |
Number of fatalities | 0‡ | 0+ | 0+ |
Employee Safety7 by Region | placeholder |
placeholder |
placeholder |
Lost Workday Case rate8 | placeholder |
placeholder |
placeholder |
Asia Pacific | 0.06‡ | 0.02+ | 0.06+ |
Europe, Middle East & Africa | 0.06‡ | 0.04+ | 0.05+ |
Latin America | 0.07‡ | 0.08+ | 0.06+ |
North America | 0.07‡ |
0.07+ |
0.08+ |
Total Recordable Injury Rate | placeholder |
placeholder |
placeholder |
Asia Pacific | 0.14‡ | 0.08+ | 0.12+ |
Europe, Middle East & Africa | 0.29‡ | 0.21+ | 0.27+ |
Latin America | 0.26‡ | 0.18+ | 0.25+ |
North America | 0.37‡ | 0.35+ | 0.42+ |
Serious Injury and Illness Case rate | placeholder |
placeholder |
placeholder |
Asia Pacific | 0.01‡ | 0.02+ | 0.04+ |
Europe, Middle East & Africa | 0.02‡ | 0.01+ | 0.03+ |
Latin America | 0.02‡ | 0.01+ | 0.02+ |
North America | 0.04‡ | 0.04+ | 0.06+ |
Road Safety
Road Safety9 | 2021 | 2020 | 2019 |
---|---|---|---|
Crashes per Million Miles (CPMM) rate | 4.83 | 4.86 | 5.54 |
Injuries per Million Miles (IPMM) rate | 0.07 | 0.05 | 0.06 |
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 As of October 2020, new categories were added to allow employees to actively decline self-identification or remain unidentified. Where the value for 'Declined to answer' rounded to zero, we excluded from the reported table.
2 “Employee” is defined as an individual working full-time or part-time, excluding fixed-term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies, and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Fixed-term contracts make up less than 5% of total employees plus individuals on fixed-term contracts. Johnson & Johnson is not currently able to disclose the number of individuals on fixed-term contracts in 2021. We are working to make this information available in future.
3 Professional positions are defined as pay grades 20-26. Management positions are defined as pay grade 30 and above; executives are defined as employees reporting directly to the CEO.
4 Values have been rounded to the nearest tenth. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
5 Career progression movement includes upward promotion and lateral transfer, and excludes employees in the R&D organizations.
6 Category includes employees who don’t have a merit plan as part of their compensation package.
7 LWDC rate, TRIR, SIIC rate, and fatalities are calculated for Johnson & Johnson employees and contingent workers. Contingent workers (i.e., workers supplied by third-party agencies that are the worker’s employer of record) are intended to supplement or temporarily replace existing workforce and are directly supervised by a Johnson & Johnson employee.
8 “Lost days” are calendar days counted beginning the day after an incident has taken place.
9 CPMM and IPMM rates are based on Safe Fleet data. Rate calculation methodology uses both actual and estimated data on miles driven. We collect Safe Fleet data on employees who drive Company-owned or -leased and personally owned vehicles for Company business. Employees in the latter category are those who: 1) drive for Company business as a “regular part“ of their job duties, and 2) receive a car allowance to purchase their own vehicle and/or are reimbursed for vehicle expenses such as fuel, maintenance, insurance and other miscellaneous charges associated with vehicle upkeep.
Environmental Health
Energy Use1 | 2021 | 2020 | 2019 |
---|---|---|---|
Total energy use (TJ) | 11,947 | 11,954 | 12,702 |
From renewable sources | 3,355 | 3,483 | 2,118 |
From non-renewable sources | 8,593 | 8,471 | 10,584 |
Energy intensity ratio (TJ/billion $)2 | 127 | 145 | 155 |
Percentage change in energy intensity compared to 2016 baseline (TJ/billion $)3 | (29)% | (19)% | (13)% |
Percent renewable electricity by region | placeholder |
placeholder |
placeholder |
North America | 67%◊ | 72%∆ | Not reported |
Europe | 79%◊ | 82%∆ | Not reported |
Purchased energy use by type (TJ)1 | placeholder |
placeholder |
placeholder |
Electricity | 5,885 | 5,922 | 6,421 |
Natural gas | 4,480 | 4,412 | 4,808 |
Diesel | 507 | 613 | 465 |
Direct heating/cooling | 312 | 265 | 274 |
Propane | 44 | 53 | 51 |
Biogas | 31 | 28 | 26 |
Fuel oil | 9 | 13 | 15 |
Total purchased energy | 11,267 | 11,306 | 12,059 |
On-site generated energy use by type (TJ)1 | placeholder |
placeholder |
placeholder |
Co-generation | 456 | 418 | 439 |
Wind | 111 | 129 | 97 |
Solar PV | 86 | 73 | 78 |
Geothermal | 21 | 18 | 6 |
Fuel cell | 4 | 7 | 22 |
Biomass | 3 | 2 | 2 |
Total on-site generated energy | 681 | 647 | 643 |
On-site clean/renewable energy capacity by type4 | placeholder |
placeholder |
placeholder |
Solar PV | 44% | 37% | 39% |
Co-generation | 29% | 32% | 31% |
Wind | 23% | 25% | 25% |
Geothermal | 2% | 3% | 2% |
Biomass | 2% | 2% | 2% |
Fuel cell | 1% | 1% | 1% |
On-site clean/renewable energy technology capacity, (MW) | 67.2 | 61.4 | 62.7 |
Electricity generated from renewable sources | 52%◊ | 54%∆ | 30%∆ |
Environmental Health
Greenhouse Gas (GHG) Emissions | 2021 | 2020 | 2019 |
---|---|---|---|
Scope 1 GHG emissions, total (MT CO2e)5 | 367,674◊ | 363,686∆ | 426,074∆ |
Scope 1 GHG emissions by source (MT CO2e)5 | placeholder |
placeholder |
placeholder |
Facilities1 | 264,669 | 268,448 | 288,200 |
Sales fleet16 | 81,093 | 76,720 | 114,681 |
Refrigerants17 | 13,569 | 14,139 | 12,979 |
Aviation | 8,344 | 4,378 | 10,215 |
Scope 2 GHG emissions, facilities (MT CO2e)1, 5 | placeholder |
placeholder |
placeholder |
Location-based | 616,093◊ | 610,320∆ | 629,674∆ |
Market-based6 | 397,086◊ | 383,480∆ | 542,756∆ |
Scope 1 + Scope 2 GHG emissions, total (MT CO2e) | 764,760◊ | 747,166∆ | 968,830∆ |
GHG emissions intensity (Scope 1 + Scope 2) by revenue (MT CO2e/million $) | 8 | 9 | 12 |
Percentage decrease in GHG emissions intensity (Scope 1 + Scope 2) by revenue compared to 2016 baseline (MT CO2e /million $) | 50% | 44% | 27% |
Scope 3 GHG emissions, by source (MT CO2e)5, 15 | placeholder |
placeholder |
placeholder |
Purchased goods and services7 | 6,605,416◊ | 6,244,849∆ | 6,211,425∆ |
Upstream transportation and distribution7 | 1,541,624◊ | 1,456,295∆ | 1,512,901∆ |
Business travel7, 8 | 225,317◊ | 218,535∆ | 757,832∆ |
Employee commuting9 | 117,192 | 131,128 | 267,881 |
Capital goods7 | 207,060◊ | 201,126∆ | 222,883∆ |
Fuel- and energy-related activities10 | 241,021◊ | 183,087∆ | 190,386∆ |
Upstream leased assets11 | 24,657◊ | 28,969∆ | 39,830∆ |
Waste generated in operations12 | 8,759◊ | 8,065∆ | 3,618∆ |
Downstream transportation and distribution13 | Available 12/22 | 55,332◊ | 58,184∆ |
Use of sold products17 | placeholder |
placeholder |
placeholder |
Direct | 76,721 | 108,165 | 168,612 |
Indirect | 8,087,123 | 7,635,771 | 7,248,612 |
End-of-life treatment of sold products14 | 223,963 | 223,038 | 209,994 |
Restatement of Select Scope 3 Categories by Source (MT CO2e)5, 15
Capital Relief Fund
CO2 Capital Relief Fund | 2021 | 2020 | 2019 |
---|---|---|---|
Number of projects approved | 11 | 16 | 16 |
Number of projects completed | 19 | 10 | 14 |
Cumulative projects approved since 2005 | 291 | 280 | 266 |
Cumulative projects completed since 2005 | 260 | 241 | 231 |
Amount spent on projects, annual (millions) | $24 | $33 | $25 |
Cumulative spend on completed projects since 2005 (millions) | $470 | $445 | $431 |
Total annual energy cost savings as a result of completed projects since 2005 (millions) | $87 | $83 | $80 |
Total annual energy savings as a result of completed projects since 2005 (TJ)18 | 2,512 | 2,345 | 2,247 |
Total annual GHG emissions avoided as a result of completed projects since 2005 (MT CO2e) | 313,965 | 298,905 | 287,931 |
Air Emissions (MT)
Air Emissions (MT) | 2021 | 2020 | 2019 |
---|---|---|---|
Hazardous air pollutant (HAP) emissions | 43.35 | 34.62 | 39.98 |
Mono-nitrogen oxides (NOx) emissions | 37◊ | 45∆ | 35∆ |
Ozone-depleting substances emissions | 1.28 | 1.86 | 1.11 |
Ozone-depleting substances emissions (MT of CFC-11 equivalents) |
0.05 | 0.09 | 0.05 |
Particulate matter (PM) emissions | 67.10 | 89.20 | 116.56 |
Refrigerant emissions | 8.65 | 9.58 | 8.01 |
Sulfur oxides (SOx) emissions | 53◊ | 65∆ | 51∆ |
Volatile organic compound (VOC) emissions | 449.15 | 366.08 | 394.07 |
Water Use (Million m3)
Water Use (Million m3) | 2021 | 2020 | 2019 |
---|---|---|---|
Total water withdrawn | 11.04◊ | 11.09 | 11.71 |
Total water consumed19 | 3.89◊ | 3.77 | 4.01 |
Total water recycled and reused | 0.81◊ | 0.75 | 0.81 |
Total water discharge19 | 7.15◊ | 7.32 | 7.67 |
Percentage of water withdrawn in regions of high or extremely high baseline water stress | 40%◊ | 39% | 39% |
Percentage of water consumed in regions of high or extremely high baseline water stress | 52%◊ | 50% | 48% |
Water withdrawn by source | placeholder |
placeholder |
placeholder |
Municipal | 7.70 | 7.72 | 8.68 |
Groundwater | 3.06 | 3.08 | 2.85 |
Other | 0.09 | 0.06 | 0.07 |
Rainwater | 0.15 | 0.06 | 0.03 |
Gray water | 0.02 | 0.15 | 0.06 |
Surface water | 0.01 | 0.02 | 0.02 |
Total water use | 11.04 | 11.09 | 11.71 |
Water withdrawn in areas of high or extremely high baseline water stress by source | placeholder |
placeholder |
placeholder |
Municipal | 3.20 | Not reported | Not reported |
Groundwater | 1.02 | Not reported | Not reported |
Rainwater | 0.13 | Not reported | Not reported |
Other | 0.09 | Not reported | Not reported |
Gray water | 0.01 | Not reported | Not reported |
Surface water | 0 | Not reported | Not reported |
Total water use in areas of high or extremely high baseline water stress |
4.45 | Not reported | Not reported |
Water discharge by destination | placeholder |
placeholder |
placeholder |
Wastewater treatment plant | 4.81 | 5.12 | 5.46 |
Surface water | 1.85 | 2.00 | 2.12 |
Irrigation | 0.26 | 0.19 | 0.19 |
Ocean | 0.18 | 0.18 | 0.12 |
Other | 0.06 | 0.07 | 0.06 |
Total water discharge | 7.15 | 7.56 | 7.95 |
Operational Waste (MT)
Operational Waste (MT) | 2021 | 2020 | 2019 |
---|---|---|---|
Total waste generated20 | 194,836 | 183,558 | 195,272 |
Hazardous waste | 52,180 | 53,944 | 53,425 |
Non-hazardous waste20 | 142,656 | 129,614 | 141,848 |
Waste diverted from disposal | placeholder |
placeholder |
placeholder |
Hazardous waste | placeholder |
placeholder |
placeholder |
Recycled | 25,207 | 22,813 | 25,897 |
Energy recovery | 16,599 | 19,836 | 16,684 |
Reused | 1,457 | 2,234 | 1,756 |
Non-hazardous waste | placeholder |
placeholder |
placeholder |
Recycled | 92,206 | 82,184 | 83,118 |
Energy recovery | 18,724 | 17,969 | 20,793 |
Reused | 12,451 | 13,271 | 13,282 |
Total waste diverted from disposal | 166,645 | 158,309 | 161,530 |
Waste directed to disposal | placeholder |
placeholder |
placeholder |
Hazardous waste | placeholder |
placeholder |
placeholder |
Landfilled | 2,380 | 2,533 | 3,449 |
Incinerated | 5,146 | 4,824 | 3,373 |
Bio/chemical treatment | 1,269 | 1,599 | 2,181 |
Other | 121 | 104 | 86 |
Non-hazardous waste | placeholder |
placeholder |
placeholder |
Landfilled20 | 9,424 | 8,384 | 12,512 |
Incinerated | 1,965 | 2,799 | 2,923 |
Bio/chemical treatment | 7,808 | 4,948 | 9,192 |
Other | 78 | 59 | 28 |
Total waste directed to disposal | 28,192 | 25,250 | 33,744 |
EH&S Compliance and Certifications
EH&S Compliance and Certifications | 2021 | 2020 | 2019 |
---|---|---|---|
Number of manufacturing and R&D sites certified to ISO 1400121, 22 | 92‡ | 95+ | 100+ |
Percentage of manufacturing and R&D sites certified to ISO 1400121, 22 | 89%‡ | 96%+ | 97%+ |
Percentage of manufacturing and R&D sites certified to ISO 4500121, 22 | 17%‡ | 21%+ | 24%+ |
Number of environmental non-compliances23, 24 | 34‡ | 50+ | 61+ |
Fines paid for environmental non-compliances (thousands)24, 25 | $3.6‡ | $5.9+ | $41+ |
LEED Buildings
LEED Buildings | 2021 | 2020 | 2019 |
---|---|---|---|
Number of newly LEED-certified Johnson & Johnson buildings (annual) | 7 | 6 | 2 |
Number of Johnson & Johnson buildings that are LEED-certified (total) | 67 | 60 | 54 |
Percentage of Johnson & Johnson built space that is LEED-certified (total) | 15.9% | 14.5% | 13% |
Total area of office and building space that is LEED certified (million square feet) | 9.4 | 8.7 | 8.0 |
Product End of Life (Millions)
Product End of Life (Millions) | 2021 | 2020 | 2019 |
---|---|---|---|
Number of medical devices collected in U.S. | 0.93 | 1.60 | 2.45 |
Number of medical devices reprocessed in U.S. | 0.39 | 0.67 | 1.12 |
∆ See ERM CVS's independent assurance statements in the 2019 and 2020 Health for Humanity Report.
‡ See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2019 and 2020 Health for Humanity Report.
1 Includes site-specific data from all Johnson & Johnson owned and leased sites over 50,000 square feet where Johnson & Johnson has operational control as well as manufacturing and R&D sites under 50,000 square feet, unless otherwise noted.
2 Our diverse product portfolio makes it difficult to track an organization-specific metric; therefore, we use revenue as a denominator for energy intensity. Energy intensity ratio includes electricity, stationary fuels and district heating and cooling.
3 2019 and 2020 figures are restated to reflect updated baseline.
4 Values have been rounded to the nearest whole number. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
5 In accordance with guidance from World Resources Institute Corporate Accounting and Reporting Standard, we restated the 2019 and 2020 values to reflect newly released electricity grid emission factors as well as the addition or removal of acquisitions and divestitures. This threshold for restatement deviates from the one included in the About This Report section. We do not currently use purchases, sales or transfers of offsets in our GHG accounting. Gases covered in these calculations include CO2, CH4, N2O and HFCs. Perfluorinated chemicals, sulfur hexafluoride and nitrogen trifluoride do not result from our operations. Biogenic CO2 emissions in 2021 were 1,758 MT CO2. Electricity emission factors are obtained from the International Energy Agency’s CO2 Emissions from Fuel Combustion Report; the U.S. Environmental Protection Agency's eGRID publication for location-based Scope 2 reporting, and supply contracts and residual emission factors, where available, for market-based Scope 2 reporting. Fuel emission factors are obtained from the EPA Climate Leadership publication. Global Warming Potentials are obtained from the Intergovernmental Panel on Climate Change Fifth Assessment Report. The chosen consolidation approach for emissions is operational control.
6 We did not report Scope 2 emissions using the market-based method prior to 2017. Starting from 2017, we have reported Scope 2 emissions using both location-based and market-based methods, based on the latest Scope 2 guidance from the World Resources Institute in the Corporate Accounting and Reporting Standard.
7 2016-2020 data for certain Scope 3 upstream categories is restated to adjust for inflation. Emissions were calculated using Company spend in the reporting year paired with appropriate economic input/output (IO) emission factors from the Carnegie Mellon 2002 data set. Where more specific primary data were able to be obtained, they were used in place of the IO calculation methodology.
8 Business travel emissions from personal vehicle travel reflect CO2 only.
9 Data from a 2021 survey of a sample of employees in all regions, extrapolated for all employees globally, were used to estimate average employee commuting and remote working emissions intensity per employee. This value was used to calculate 2021 emissions from Employee Commuting.
10 Emissions from fuel- and energy-related activities were calculated for emissions from transmission and distribution (T&D) losses from purchased electricity, well-to-tank (WTT) emissions from purchased electricity, WTT emissions from T&D losses, and WTT emissions from purchased fuels. Emissions were calculated using IEA loss factors for electricity and DEFRA WTT emission factors for fuels and electricity.
11 Emissions from Upstream Leased Assets were calculated by applying the energy intensity from office locations in our Scope 1 and Scope 2 footprint to the building area of leased assets less than 50,000 square feet, or those greater than 50,000 square feet outside of our operational control which are excluded from Scope 1 and Scope 2 reporting.
12 Emissions from Waste Generated in Operations were calculated for both non-hazardous and hazardous waste from manufacturing and R&D operations using DEFRA's emissions factors for waste. In years prior to 2020, only non-hazardous waste emissions were reported.
13 Emissions from Downstream Transportation and Distribution were calculated using the U.S. EPA’s SmartWay Program and are provided for U.S. shippers only. GHG covered in these calculations include CO2 only for the 2020 calendar year, the most up-to-date available. 2021 data will be available in December of 2022 and will be reported in future reports. We have identified a level of uncertainty around the reporting boundary, and the reported value is potentially overstated.
14 Emissions from the Use of Sold Products and the End-of-Life Treatment of Sold Products were calculated using sales volumes for all Johnson & Johnson products combined with lifecycle assessment (LCA) models where sales volumes could be obtained; where they could not be obtained, sales revenues and average unit prices were used to estimate volumes. Due to the size of our product portfolio, LCAs were not performed for every Johnson & Johnson product, so products were placed into LCA categories, and a representative product LCA was applied. It should be noted that due to the assumptions that were made, Johnson & Johnson did not receive third-party limited assurance for these scopes but will work to improve these assumptions in the coming years.
15 Emissions from the Processing of Sold Products, Downstream Leased Assets, Franchises and Investments are not applicable to Johnson & Johnson operations.
16 Greenhouse gases covered in these calculations include CO2 only.
17 Includes site-specific data from all Johnson & Johnson manufacturing and R&D sites only.
18 Results from completed projects. Based on fuel and electricity reduction calculations. Avoidance of energy consumption and GHG emissions calculated by comparing energy consumption before project implementation and expected consumption after implementation using engineering estimates at the time the projects are approved.
19 Due to a unit conversion error, 2019 and 2020 figures are restated.
20 2020 figures are restated.
21 Certified to ISO 14001 or ISO 45001 means the site has received an external certification that is valid as of December 31, 2021. The decrease in sites with ISO 14001 certifications is driven in part by a decrease in overall Johnson & Johnson-owned manufacturing and R&D sites.
22 The denominator of total manufacturing and R&D sites excludes small R&D and manufacturing sites (defined as having less than 50 employees) and newly acquired sites (i.e., owned less than three years as of December 31, 2021).
23 Environmental non-compliances represent instances of non-compliance with environmental regulatory requirements or laws that were either (i) self-reported to authorities in the reporting year or (ii) identified by authorities and the non-compliance occurred in the reporting year. The authorities include regional, national, state/country/province and local/city regulatory agencies.
24 Environmental non-compliances and fines paid exclude newly acquired sites (i.e., owned less than two years as of December 31, 2021).
25 Fines paid for environmental non-compliances include those paid in the reporting year. It does not include fines assessed and/or under negotiation that were not paid as of December 31, 2021.
Accountability & Innovation
Supply Base Overview | 2021 | 2020 | 2019 |
---|---|---|---|
Number of Johnson & Johnson suppliers | 45,324 | 51,280 | 57,663 |
Total Johnson & Johnson supplier spend (billions)1 | $34.8 | $30.6 | $30.1 |
Supplier spend contracted by region1 | placeholder |
placeholder |
placeholder |
Asia Pacific | 9% | 11% | 11% |
Europe, Middle East & Africa | 34% | 33% | 33% |
Latin America | 3% | 3% | 4% |
North America | 55% | 53% | 52% |
Supplier spend contracted by business segment1 | placeholder |
placeholder |
placeholder |
Pharmaceutical | 37% | 34% | 31% |
MedTech2 | 28% | 24% | 24% |
Consumer Health2 | 24% | 30% | 32% |
Corporate | 12% | 12% | 13% |
Supplier Engagement
Supplier Engagement | 2021 | 2020 | 2019 |
---|---|---|---|
Number of suppliers invited to participate in the CDP Supply Chain Climate program | 388 | 423 | 344 |
Percentage participated | 82% | 80% | 84% |
Number of suppliers invited to participate in the CDP Supply Chain Water program | 135 | 153 | 112 |
Percentage participated | 75% | 79% | 84% |
EcoVadis assessments completed3 | 881 | 1,119 | 750 |
Supplier risk ranking based on EcoVadis assessments | placeholder |
placeholder |
placeholder |
Low risk | 635 | 729 | 462 |
Medium risk | 213 | 349 | 259 |
High risk | 33 | 41 | 29 |
Diverse Supplier Spend in the U.S. (Millions)5
Diverse Supplier Spend in the U.S. (Millions)5 | 2021 | 2020 | 2019 |
---|---|---|---|
Tier 1 Diverse | $2,214 | $1,670 | $1,610 |
Total LGBT-owned | $9.2 | $4.5 | $3.7 |
Total Veteran- and disabled veteran-owned | $197.4 | $193.2 | $169.6 |
Small business | $2,641 | $2,650 | $2,610 |
Percentage of total supplier spend attributable to small suppliers | 14% | 17% | 18% |
Percentage of total supplier spend attributable to diverse suppliers | 12% | 11% | 11% |
Total Global Impact Spend (billions)4 | 5.22◊ | Not reported | Not reported |
% increase of Tier 1 diverse spend with U.S. Black- and Hispanic-owned businesses | 31% | Not reported | Not reported |
Diverse Supplier Spend, Global (Millions)5
Diverse Supplier Spend, Global (Millions)5 | 2021 | 2020 | 2019 |
---|---|---|---|
Number of countries outside the U.S. tracking diversity & inclusion indicators | 18 | 16 | 16 |
Tier 1 Women-owned | $1,223.9 | $826.0 | Not reported |
Tier 1 Minority-owned | $1,785.1 | $1,223.4 | Not reported |
Tier 1 LGBT-owned | $11.0 | Not reported | Not reported |
Tier 1 Veteran-owned and disabled veteran-owned | $127.9 | Not reported | Not reported |
Total Veteran-owned and disabled veteran-owned | $206.3 | Not reported | Not reported |
Tier 1 Diverse supplier spend in countries outside the U.S. | $668.7 | $290.0 | Not reported |
Total Tier 1 Diverse (billions) | $2.9 | Not reported | Not reported |
Tier 2 Diverse | $508.7 | $372.1 | Not reported |
Supplier Audits
Supplier Audits | 2021 | 2020 | 2019 |
---|---|---|---|
Supplier Environment, Health and Safety (EH&S) audits | placeholder |
placeholder |
placeholder |
EH&S audits and technical visits completed, total | 164 | 156 | 206 |
EH&S audits | 124 | 104 | 134 |
Technical visits6 | 40 | 52 | 72 |
EH&S audits and technical visits by region | placeholder |
placeholder |
placeholder |
Asia Pacific | 133 | 133 | 174 |
Europe, Middle East & Africa | 11 | 13 | 13 |
Latin America | 10 | 2 | 7 |
North America | 10 | 8 | 12 |
Number of suppliers identified as high risk for non-conformance to Johnson & Johnson Responsibility Standards for Suppliers | 21 | 24 | 32 |
Number of critical EH&S findings7 identified as a result of EH&S audits | 9 | 2 | 34 |
Safety-related findings | 8 | 2 | 23 |
Environmental-related findings | 1 | 0 | 11 |
Supplier social audits8 | placeholder |
placeholder |
placeholder |
Supplier social audits completed, total | 11 | 5 | 50 |
Completed using SMETA 4-Pillar protocol | 11 | 5 | 37 |
Social audits completed by region | placeholder |
placeholder |
placeholder |
Asia Pacific | 8 | 4 | 37 |
Europe, Middle East & Africa | 2 | 0 | 5 |
Latin America | 1 | 1 | 6 |
North America | 0 | 0 | 2 |
Number of critical findings7 identified as a result of supplier social audits | 1 | 3 | 5 |
Board of Directors' Composition
Board of Directors' Composition | 2021 | 2020 | 2019 |
---|---|---|---|
Number of Directors | 14 | 14 | 14 |
Number of Independent Directors | 13 | 13 | 13 |
Percentage of Independent Directors | 93% | 93% | 93% |
Independent Lead Director | Yes | Yes | Yes |
Independent Audit Committee | Yes | Yes | Yes |
Independent Compensation & Benefits Committee | Yes | Yes | Yes |
Independent Nominating & Corporate Governance Committee | Yes | Yes | Yes |
Independent Regulatory Compliance Committee | Yes | Yes | Yes |
Independent Science, Technology & Sustainability Committee | Yes | Yes | Yes |
Number of regular and special meetings held by the Board of Directors | 17 | 10 | 9 |
Code of Business Conduct (CBC) Training
Code of Business Conduct (CBC) Training | 2021 | 2020 | 2019 |
---|---|---|---|
Percentage of active employees who completed biennial CBC training | 98% | Not reported | 97% |
Percentage of active contingent workers9 who completed biennial CBC training | 97% | Not reported | 91% |
Code of Business Conduct (CBC) Compliance
Code of Business Conduct (CBC) Compliance | 2021 | 2020 | 2019 |
---|---|---|---|
Percentage of senior leaders certified the compliance of their organizations with the CBC10 | 100% | 100% | 100% |
Number of warning letters or untitled letters issued by OPDP or APLB in the U.S.11 | 0 | 0 | 0 |
Health Care Compliance (HCC) Training
Health Care Compliance (HCC) Training | 2021 | 2020 | 2019 |
---|---|---|---|
Number of relevant Johnson & Johnson employees that completed HCC training that includes anti-corruption section | 98,000 | 81,000 | 90,000 |
Percentage of sales and marketing employees who completed HCC training | 97% | 96% | 95% |
Inquiries and Complaints as Recorded with Our Credo Integrity Line by Category13
Inquiries and Complaints as Recorded with Our Credo Integrity Line by Category13 | 2021 | 2020 | 2019 |
---|---|---|---|
Human Resources-related | 55%‡ | 51%+ | 60% |
Business integrity-related | 14%‡ | 12%+ | 6% |
Other | 9%‡ | 11%+ | 8% |
General information questions | 8%‡ | 10%+ | 11% |
Financial-related | 7%‡ | 14%+ | 13% |
Human rights-related | 5%‡ | Not reported | Not reported |
Product quality- and patient safety-related | 2%‡ | 2%+ | 2% |
Compliance-Related Allegations Investigated Through Triage Committee
Compliance-Related Allegations Investigated Through Triage Committee | 2021 | 2020 | 2019 |
---|---|---|---|
Number of compliance-related allegations investigated | 661‡ | 559+ | 738 |
Percentage of compliance-related allegations investigated by category | placeholder |
placeholder |
placeholder |
Healthcare compliance | 48%‡ | 41%+ | 40% |
Financial | 43%‡ | 51%+ | 50% |
Other | 9%‡ | 8%+ | 10% |
Collective Bargaining Agreements
Collective Bargaining Agreements | 2021 | 2020 | 2019 |
---|---|---|---|
Employees covered by collective bargaining agreements14 | 30%‡ | 23% | 20% |
Product Quality Indicators
Product Quality Indicators | 2021 | 2020 | 2019 |
---|---|---|---|
Number of regulatory inspections of Johnson & Johnson sites by worldwide health authorities | 448‡ | 452+ | 521+ |
Percentage of regulatory inspections that resulted in zero observations | 76%‡ | 82%+ | 73%+ |
Number of FDA inspections of Johnson & Johnson sites | 9‡ | 10+ | 17+ |
Percentage of FDA inspections that resulted in zero observations | 56%‡ | 80%+ | 76%+ |
Average number of observations per FDA inspection | 2.4‡ | 1.7+ | 0.6+ |
Number of independent audits of Johnson & Johnson sites to ensure compliance with Johnson & Johnson Quality Policy & Standards | 170‡ | 165+ | 156+ |
Number of independent audits of external manufacturing sites to ensure compliance with Johnson & Johnson Quality Policy & Standard | 277‡ | 230+ | 264+ |
Number of FDA warning letters issued | 0‡ | 0+ | 1+ |
Product recall rate15 by business segment | placeholder |
placeholder |
placeholder |
Pharmaceutical | 0%‡ | 0%+ | 0.002% |
MedTech | 0.059%‡ | 0.034%+ | 0.041% |
Consumer Health Self-Care OTC16 | 0%‡ | 0%+ | 0.091% |
Anti-Counterfeiting
Anti-Counterfeiting | 2021 | 2020 | 2019 |
---|---|---|---|
Anti-counterfeiting best practices training delivered to customs and border patrol officials17 | 3,960 | 3,164 | Not reported |
Number of external trade groups, alliances, organizations and agencies in which Johnson & Johnson is engaged in leadership positions or industry working groups | 13 | 7 | 9 |
‡ See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 Represents spend we have control over/addressable spend, defined as products and services that procurement teams can negotiate with suppliers to meet business goals. Values have been rounded. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
2 Due to a categorization error, 2019 and 2020 figures are restated. Consumer MedTech supplier spend is included in the MedTech business segment. It had historically been reported as part of the Consumer Health business segment.
3 Supplier EcoVadis assessments are reported as of January 31 2022 may not capture suppliers that updated their assessment in January of 2022.
4 Total Global Impact Spend consists of: Tier 1 Diverse supplier spend in the U.S. (billions) and countries outside the U.S. (billions), plus Small business spend in the U.S. (billions), less overlap spend, plus Tier 2 diverse supplier spend, global (millions). U.S. suppliers can be classified as Tier 1 Diverse and Small business. The Tier 1 & Small overlap is removed to avoid double counting of the spend.
5 Except Tier 2 Diverse spend, all indicators represent spend Johnson & Johnson has control over/addressable spend, defined as products and services that procurement teams can negotiate with suppliers to meet business goals.
6 A technical visit is a follow-up visit to the initial audit.
7 We define a critical finding as evidence of very high risk to human life or potential catastrophic impact to facility, community or environment. We expect suppliers and potential suppliers to address critical findings immediately.
8 Social audits are conducted using the SMETA protocol. The PSCI protocol was phased out in 2020.
9 Temporary workers supplied by third-party agencies that are the workers' employer of record. Contingent workers are intended to supplement existing workforce or temporarily replace them.
10 Certifiers include senior leaders at VP2 level and above, selected Managing Directors and General Managers based on country or business segment risk profile, and executives of recently acquired companies.
11 OPDP: Office of Prescription Drug Promotion and APLB: Advertising and Promotional Labeling Branch of the FDA Center for Biologics Evaluation and Research.
13 Johnson & Johnson Triage Committee and case investigators have the ability to change the issue type of cases upon receipt in Our Credo Integrity Line. This occurs for 5% or fewer of cases.
14 The increase in percentage is not a reflection of new labor unions being recognized, but rather clarifying the definition of representation by labor union which expanded the qualifying population of certain countries in Asia and Latin America.
15 Product recall rate is defined as the number of lots removed from market per total globally manufactured, based on field action removals where it has been determined internally by a Quality Review Board, and aligned by Johnson & Johnson Enterprise Compliance, that there is a reasonable probability that the product may cause temporary or medically reversible adverse health consequences and, in certain cases, will cause serious adverse health consequences.
16 The Pharmaceutical and MedTech recall rate consider all products in each business segment. The Consumer Health product quality recall rate is inclusive of Consumer Health products from the Self-Care over-the-counter (OTC) business segment. It does not represent Essential Health and Skin Health/Beauty business segment products, including the voluntary recall of certain aerosol sunscreen products in 2021.
17 All employees at Johnson & Johnson are trained in the Code of Business Conduct as well as what to do if they become aware of a product complaint or adverse event. Brand protection awareness is included in both of these mandatory trainings to raise understanding and awareness of illicit trade issues among all employees. Supplemental brand protection training is also available to stakeholders and is reflected in the number above.